Feldman, Didi
Sinberger, Liat Anabel
Salmon-Divon, Mali
Ben-Dror, Judith
Shachar, Shlomit Strulov
Sonnenblick, Amir
Funding for this research was provided by:
The Parasol Center for Women's Cancer Research, The Parasol Foundation
Article History
Received: 14 June 2023
Accepted: 16 October 2023
First Online: 24 October 2023
Declarations
:
: The study was approved by the institutional review board (IRB of TEL AVIV SOURASKY MEDICAL CENTER 18–0426) and conducted in line with the principles of the Helsinki Declaration. The IRB (TEL AVIV SOURASKY MEDICAL CENTER 18–0426) waived patient informed consent due to its retrospective and anonymized design.
: Not applicable.
: Amir Sonnenblick is a consultant for Eli Lilly, Pfizer, Novartis, Roche, Gilead, MSD, Astra-Zenca and Progenetics. He receives travel, accommodations and expenses from Neopharm, Celgene, Medison and Roche. He is on the speakers' bureau at Teva, Roche, Pfizer, Novartis and Eli Lilly and receives grant support from Novartis and Roche.Shlomit Strulov Shachar is a consultant for Eli Lilly, Pfizer, Novartis, and MSD. She receives travel, accommodations and expenses from Pfizer, Gilead, Astra-Zeneca and Roche. She is on the speakers' bureau at Eli Lilly, Pfizer, Novartis, Roche, Gilead, MSD, Astra-Zeneca and Progenetics.The other authors have no potential conflicts of interest.